Bloom Science Engages Epilepsy Community at American Epilepsy Society Meeting 2025

by | Dec 3, 2025 | In the News

SAN DIEGO, Calif., December 3, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced its participation in the American Epilepsy Society (AES) 2025 Annual Meeting.

The AES meeting brings together clinicians, researchers, and patient advocates dedicated to improving outcomes in epilepsy and related disorders. Bloom’s team engaged with key opinion leaders to discuss advances in gut-brain axis research and therapeutic opportunities in rare epilepsies.

Bloom’s lead program, BL-001, is being developed with potential applications in neurological disorders including Dravet syndrome.

“We are committed to working alongside the epilepsy community to advance innovative treatment options,” said Dr. Reyes.

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bloom Science Announces Poster Presentations at Obesity Week 2025

by | Nov 4, 2025 | Press Releases

SAN DIEGO, Calif., November 4, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that clinical data from the company’s BL-001 program will be highlighted in a poster presentations at the 2025 ObesityWeek.  BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet being developed for weight loss in obesity and the potential treatment of Dravet Syndrome and DEEs (Developmental and Epileptic Encephalopathies). The 2025 ObesityWeek is being held November 4-7th in Atlanta, GA.

The presentation will summarize results from the company’s Phase 1 clinical trial, a randomized, double-blind, placebo-controlled MAD (multiple ascending dose) study evaluating 28 days of daily treatment with an oral formulation of BL-001 in healthy subjects. 

Details of the presentations are as follows:

Title: Safety, Tolerability, and Efficacy of BL-001, an Oral LBP, for Weight Loss in Healthy Volunteers

Presenting Author: Louis Licamele, PhD, Chief Development Officer, Bloom Science

Date/Time: Thursday, November 6, 2025, 2:30-3:30 p.m. EST

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Poster #2.414:

    Title: Selection of Lead Candidate Bacteria for BL-001, a Live Biotherapeutic Product in Development for the Treatment of Neurological Indications

    Presenting Author: Lisa Elmén, PhD, Sr Scientist and Andra Ionescu Tucker, PhD, Scientist, Bloom Science

    Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST

    Location: Exhibit Hall Los Angeles Convention Center

    About BL-001 and the Ketogenic Diet

    BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) being developed by Bloom Science. BL-001 is designed to replicate the therapeutic effects of the ketogenic diet. Preclinical data has demonstrated replication of the ketogenic diet therapeutic effect in epilepsy models and further demonstrated modulation of gamma aminobutyric acid (GABA) and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures.

    The ketogenic diet was initially developed in 1921 to mimic fasting as a treatment for epilepsy. The ketogenic diet is a medical diet that is very-low in carbohydrates and high in fat used to treat epilepsy in children but there is accumulating clinical evidence that the diet is effective for weight loss, reversing metabolic dysfunction and treating mental illness. While the ketogenic diet has been shown to work quite well for patients, it can be an incredible challenge to maintain indefinitely.

    About Bloom Science, Inc. 

    Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Bloom Science Recognizes Global ALS/MND Awareness Day and International Dravet Syndrome Awareness Day

    by | Jun 21, 2025 | In the News

    SAN DIEGO, Calif., June 21, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today

    today recognized Global ALS/MND Awareness Day and International Dravet Syndrome Awareness Day, honoring patients and families affected by neurodegenerative and rare neurological diseases.

    Bloom’s research platform is focused on translating insights from microbiome biology into therapeutic approaches that address metabolic and neurological dysfunction.

    “These awareness days remind us of the importance of continued innovation,” said Dr. Reyes. “We are committed to developing therapies that may improve quality of life for patients facing serious neurological conditions.”

       

      About Bloom Science, Inc. 

      Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

      Christopher Reyes, Founder and CEO of Bloom Science, joins a panel of experts to explore the Science of the Gut-Brain Axis

      by | Feb 5, 2025 | In the News

      SAN DIEGO, Calif., August 5, 2024 —Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that CEO Christopher Reyes will join a panel of entrepreneurs and researchers as they discuss the complexities of the gut microbiome and its profound impact on mental health and overall well-being.

      Gut Feelings: Exploring the Gut-Brain Connection Lecture
      Tue, Aug 6; 6:30P – 8:00P
      The Battery SF

       

       

      About Bloom Science

       

       

       

      Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.

       

       

       

       

       

       

      Bloom Science to Participate at Upcoming Patient Advocacy Conferences

      by | Feb 5, 2025 | In the News

      SAN DIEGO, Calif., June 20, 2024 — Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that the company will participate in two upcoming patient advocacy conferences.

       

      2024 Dravet Syndrome Foundation Conference in Minneapolis
      Date: June 20-22, 2024
      Location: Minneapolis

       

      ALS Nexus 2024
      Date: July 14 – 17, 2024
      Location: Dallas

       

      Poster Presentation: Development of BL-001 for the Treatment of ALS through Multiple Gut-Brain Mediated Pathways. PResenter: Christopher Reyes, PhD

       

       

       

      About Bloom Science

       

       

       

      Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.